Literature DB >> 21656024

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

C Marchetti1, A Di Carlo, F Facchiano, C Senatore, R De Cristofaro, A Luzi, M Federici, M Romani, M Napolitano, M C Capogrossi, A Germani.   

Abstract

AIMS/HYPOTHESIS: High mobility group box 1 (HMGB1) is a cytokine with a key role in tissue regeneration and angiogenesis. Previous studies have shown that topical application of HMGB1 to skin wounds of mouse models of diabetes enhanced vessel density and accelerated wound healing, suggesting that diabetes may affect endogenous HMGB1 functions. Dipeptidyl peptidase IV (DPP-IV/CD26) is a protease whose activity is increased in diabetes and whose inhibition improves glucose tolerance. Since HMGB1 contains potential DPP-IV cleavage sites, we determined whether HMGB1 may be a substrate for DPP-IV and whether DPP-IV-mediated cleavage may alter the biological activity of HMGB1.
METHODS: Reversed phase HPLC, mass spectrometry and western blot analyses were performed to analyse and identify HMGB1 peptides generated following DPP-IV digestion. HMGB1 angiogenic functions in the presence of DPP-IV were evaluated in vitro and in vivo. HMGB1 protein was detected in the serum of type 2 diabetic patients before and after treatment with DPP-IV inhibitors.
RESULTS: DPP-IV cleaved HMGB1 at its N-terminal region and affected its angiogenic functions. Specifically, DPP-IV inhibited HMGB1-induced endothelial cell migration and capillary-like structure formation, as well as HMGB1-mediated vascular network formation in Matrigel implants in mice. We had previously found that HMGB1 promoted endothelial cell migration through activation of extracellular regulated kinase signalling pathway. Here we showed that such an effect was abolished in the presence of DPP-IV. Finally, the N-terminal truncated form of HMGB1 was detected in the serum of type 2 diabetic patients, in whom DPP-IV inhibitors enhanced the levels of full-length HMGB1. CONCLUSIONS/
INTERPRETATION: DPP-IV cleaves HMGB1 and, via this mechanism, inhibits HMGB1 angiogenic activity. Treatment with DPP-IV inhibitors may enhance HMGB1 activity in diabetic patients, thereby improving angiogenesis in this condition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21656024     DOI: 10.1007/s00125-011-2213-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  36 in total

1.  High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells.

Authors:  Emmanouil Chavakis; Andreas Hain; Maria Vinci; Guillaume Carmona; Marco E Bianchi; Peter Vajkoczy; Andreas M Zeiher; Triantafyllos Chavakis; Stefanie Dimmeler
Journal:  Circ Res       Date:  2007-01-11       Impact factor: 17.367

Review 2.  Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications.

Authors:  J Waltenberger
Journal:  Cardiovasc Res       Date:  2001-02-16       Impact factor: 10.787

3.  Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions.

Authors:  L Pala; S Ciani; I Dicembrini; G Bardini; B Cresci; A Pezzatini; S Giannini; E Mannucci; C M Rotella
Journal:  Diabet Med       Date:  2010-06       Impact factor: 4.359

Review 4.  Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.

Authors:  Michael A Nauck
Journal:  Am J Med       Date:  2011-01       Impact factor: 4.965

5.  Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells.

Authors:  Carmen Fiuza; Michael Bustin; Shefali Talwar; Margaret Tropea; Eric Gerstenberger; James H Shelhamer; Anthony F Suffredini
Journal:  Blood       Date:  2002-11-27       Impact factor: 22.113

6.  SDF-1 is both necessary and sufficient to promote proliferative retinopathy.

Authors:  Jason M Butler; Steven M Guthrie; Mehmet Koc; Aqeela Afzal; Sergio Caballero; H Logan Brooks; Robert N Mames; Mark S Segal; Maria B Grant; Edward W Scott
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

7.  The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

Authors:  Gian Paolo Fadini; Elisa Boscaro; Mattia Albiero; Lisa Menegazzo; Vera Frison; Saula de Kreutzenberg; Carlo Agostini; Antonio Tiengo; Angelo Avogaro
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 19.112

8.  Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8.

Authors:  Katerina Ajami; Melissa R Pitman; Claire H Wilson; Joohong Park; R Ian Menz; Amanda E Starr; Jennifer H Cox; Catherine A Abbott; Christopher M Overall; Mark D Gorrell
Journal:  FEBS Lett       Date:  2008-02-12       Impact factor: 4.124

9.  Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.

Authors:  Aine M McKillop; Nicola A Duffy; John R Lindsay; Finbarr P M O'Harte; Patrick M Bell; Peter R Flatt
Journal:  Diabetes Res Clin Pract       Date:  2007-09-29       Impact factor: 5.602

10.  Active Sequences Collection (ASC) database: a new tool to assign functions to protein sequences.

Authors:  Angelo M Facchiano; Antonio Facchiano; Francesco Facchiano
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

View more
  22 in total

1.  Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction.

Authors:  Hye Sook Min; Jung Eun Kim; Mi Hwa Lee; Hye Kyoung Song; Young Sun Kang; Mi Jin Lee; Ji Eun Lee; Hyun Wook Kim; Jin Joo Cha; Young Yoon Chung; Young Youl Hyun; Jee Young Han; Dae Ryong Cha
Journal:  Lab Invest       Date:  2014-03-31       Impact factor: 5.662

Review 2.  The Vasculature in Prediabetes.

Authors:  David H Wasserman; Thomas J Wang; Nancy J Brown
Journal:  Circ Res       Date:  2018-04-13       Impact factor: 17.367

Review 3.  Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

Authors:  Larry K Golightly; Caitlin C Drayna; Michael T McDermott
Journal:  Clin Pharmacokinet       Date:  2012-08-01       Impact factor: 6.447

Review 4.  Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.

Authors:  Bárbara Torrecillas-Baena; María Ángeles Gálvez-Moreno; José Manuel Quesada-Gómez; Gabriel Dorado; Antonio Casado-Díaz
Journal:  Stem Cell Rev Rep       Date:  2021-10-22       Impact factor: 5.739

5.  Alarmin high-mobility group B1 (HMGB1) is regulated in human adipocytes in insulin resistance and influences insulin secretion in β-cells.

Authors:  R Guzmán-Ruiz; F Ortega; A Rodríguez; R Vázquez-Martínez; A Díaz-Ruiz; S Garcia-Navarro; M Giralt; A Garcia-Rios; D Cobo-Padilla; F J Tinahones; J López-Miranda; F Villarroya; G Frühbeck; J M Fernández-Real; M M Malagón
Journal:  Int J Obes (Lond)       Date:  2014-02-28       Impact factor: 5.095

Review 6.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

7.  The Dipeptidyl Peptidases 4, 8, and 9 in Mouse Monocytes and Macrophages: DPP8/9 Inhibition Attenuates M1 Macrophage Activation in Mice.

Authors:  Yannick Waumans; Gwendolyn Vliegen; Lynn Maes; Miche Rombouts; Ken Declerck; Pieter Van Der Veken; Wim Vanden Berghe; Guido R Y De Meyer; Dorien Schrijvers; Ingrid De Meester
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

8.  Dichotomous Role of Plasmin in Regulation of Macrophage Function after Acetaminophen Overdose.

Authors:  Katherine Roth; Jenna Strickland; Nikita Joshi; Meihong Deng; Rebekah C Kennedy; Cheryl E Rockwell; James P Luyendyk; Timothy R Billiar; Bryan L Copple
Journal:  Am J Pathol       Date:  2019-08-02       Impact factor: 4.307

Review 9.  The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

Authors:  Marcel H A Muskiet; Mark M Smits; Linde M Morsink; Michaela Diamant
Journal:  Nat Rev Nephrol       Date:  2013-12-24       Impact factor: 28.314

10.  Alerting the body to tissue injury: The role of alarmins and DAMPs in cutaneous wound healing.

Authors:  Traci A Wilgus
Journal:  Curr Pathobiol Rep       Date:  2018-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.